Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GPC Biotech has received notice from Celgene of its decision to terminate its co-development and license agreement with GPC Biotech for satraplatin in Europe, Turkey, the Middle East, Australia and New Zealand. All rights to these territories will be returned to GPC Biotech.
Subscribe to our email newsletter
Bernd Seizinger, CEO of GPC Biotech, said: “We are disappointed, but we understand Celgene’s decision given their recent withdrawal of the marketing authorization application for satraplatin in Europe.
“We plan to decide in the near future the next steps regarding the development of satraplatin, and we will continue to focus our other efforts on advancing our RGB-286638 kinase inhibitor into the clinic and exploring various merger and acquisition opportunities.”